Evidence map›Paper›PMID 31244784›Full record

ReviewFrontiers in microbiology2019

The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy.

Pei Pei Chong, Voon Kin Chin, Chung Yeng Looi, Won Fen Wong, Priya Madhavan, Voon Chen Yong

Erratum issued Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04716738 (Sexual Dysfunction, Quality of Life and Visceral Hyperalgesia in Women With Irritable Bowel Syndrome), which is not on this map. Cited by 164 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 5 pooled it
29.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04716738 unknown statusnot on this mapstarted 2023, after this paper: background citation

Sexual Dysfunction, Quality of Life and Visceral Hyperalgesia in Women With Irritable Bowel Syndrome

Typeobservational_patient_registrySponsorHospital General de MexicoRan2023 to 2023Enrolled20ConditionsIrritable Bowel Syndrome, Sexual DysfunctionArmsBlood analyses and coprological
3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 5 syntheses or guidelines pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Efficacy and dose response ofWorld journal of gastroenterology · 2023
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Nutrients · 2020
    Trial
  18. Trial
  19. Gut microbes
    Trial
  20. Trial

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pei Pei ChongSchool of Biosciences, Taylor's University, Subang Jaya, Malaysia.
Voon Kin ChinSchool of Biosciences, Taylor's University, Subang Jaya, Malaysia.
Chung Yeng LooiSchool of Biosciences, Taylor's University, Subang Jaya, Malaysia.
Won Fen WongDepartment of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Priya MadhavanSchool of Medicine, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia.
Voon Chen YongSchool of Biosciences, Taylor's University, Subang Jaya, Malaysia.
Taylor's University · MYUniversity of Malaya · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irritable bowel syndrome (IBS) is a functional disorder which affects a large proportion of the population globally. The precise etiology of IBS is still unknown, although consensus understanding proposes IBS to be of multifactorial origin with yet undefined subtypes. Genetic and epigenetic factors, stress-related nervous and endocrine systems, immune dysregulation and the brain-gut axis seem to be contributing factors that predispose individuals to IBS. In addition to food hypersensitivity, toxins and adverse life events, chronic infections and dysbiotic gut microbiota have been suggested to trigger IBS symptoms in tandem with the predisposing factors. This review will summarize the pathophysiology of IBS and the role of gut microbiota in relation to IBS. Current methodologies for microbiome studies in IBS such as genome sequencing, metagenomics, culturomics and animal models will be discussed. The myriad of therapy options such as immunoglobulins (immune-based therapy), probiotics and prebiotics, dietary modifications including FODMAP restriction diet and gluten-free diet, as well as fecal transplantation will be reviewed. Finally this review will highlight future directions in IBS therapy research, including identification of new molecular targets, application of 3-D gut model, gut-on-a-chip and personalized therapy.

Indexed as

fecal transplantIBS animal modelirritable bowel syndromemicrobiomemicrobiota dysbiosis

Identifiers

PMID31244784
PMCPMC6579922
OpenAlexW2951836243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.